Page values for "Insulin Glargine"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Insulin glargine |
| brand | String | Lantus, Basaglar, Semglee, Toujeo (U-300) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Insulins|Insulin]] • [[:Category:Long-acting_insulins|Long-acting insulin analog]] • [[:Category:Basal_insulins|Basal insulin]] |
| mechanism | String | '"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. |
| uses | String | '"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' |
| starting_dose | String | ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose |
| preparations | String | 100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens |
| fda_max | String | Titrated to glucose; no fixed ceiling |
| pill_id | Text | |
| routes | List of String, delimiter: , | Subcutaneous (never IV; not for use in insulin pumps) |
| onset | String | 1-2 hours |
| duration | String | ~24 hours per dose (peakless profile by design) |
| halflife | String | ~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' |
| bioavailability | String | ~100% from subcutaneous depot (by definition of the route) |
| pregnancy | String | Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |